Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40

NCT06224309 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06224309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Recruiting
Start date
June 10, 2024
Completion date
September 15, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, waldenström macroglobulinemia